Article

WRAL on 2024-01-31 19:35

Biogen Abandons Its Controversial Alzheimer’s Drug Aduhelm

Drugmaker Biogen said Wednesday it would abandon its ownership rights to Aduhelm, an Alzheimer’s drug that had provoked fierce criticism of the ...

Rebecca Robbins

Related news

Biogen Abandons Its Controversial Alzheimer’s Drug Aduhelm The New York Times
Biogen plans to shut down its controversial Alzheimer’s drug Aduhelm Seattle Times
Japan
First patient receives controversial Biogen Alzheimer’s drug Sydney Morning Herald
Japan , United States , Minnesota , Rochester , Massachusetts
Biogen stock plummets after it abandons Alzheimer’s drug bizjournals.com
Biogen Slashes Price of Alzheimer’s Drug Aduhelm, as It Faces Obstacles The New York Times
Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogen The New York Times
Biogen dumps dubious Alzheimer’s drug after profit-killing FDA scandal Ars Technica
Phase 4 , Switzerland , Massachusetts , Cambridge
What’s Behind Biogen’s Move To Cut Prices On Its Controversial Alzheimer’s Drug Aduhelm?Forbes
Florida , Phase 4
FFDA approves Biogen Alzheimer’s drug ft.com
FBiogen predicts preventive Alzheimer’s drug ft.com
South East Asia , China
MAlzheimer’s expert says more clinical trials are needed for controversial Biogen drug marketwatch.com
New York , San Diego , Japan
Controversial Alzheimer’s Drug Faces Critical Test Before F.D.A. Panel The New York Times
United States , Mayo Clinic , Zephyr
Panels find FDA, Biogen rushed Alzheimer’s drug Arkansas Online
Philadelphia , Cambridge
First new Alzheimer’s drug in decades receives controversial FDA approval newatlas.com
Unmet , United States
Biogen and Eisai revive plans for Alzheimer’s drug aducanumab, but prospects still shaky The Japan Times
Switzerland , Wall Street , Tokyo Prefecture , Japan , New York
FBiogen to seek Alzheimer’s drug approval ft.com
Biogen Alzheimer’s Drug Impresses in Early Study wsj.com